Figure 1.
Study design of BLISS-SC trial and subsequent open-label extension phase.
BLISS-SC: A study of belimumab administered subcutaneously in subjects with systemic Lupus Erythematosus; SC: subcutaneous.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.